Mantle Cell Lymphoma


Jun Zhu, MD, PhD with Beijing University Cancer Hospital Principal Investigator for Brukinsa

Recently, BeiGene Ltd’s lymphoma treatment Brukinsa was approved by the U.S. Food and Drug Administration. This is the first time a drug developed predominantly in China by a Chinese biopharma sponsor has been approved within America. The key clinical trials...

Pin It on Pinterest